Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
SINTEF Health Research The Research Council of Norway University of Oslo |
---|---|
Information provided by: | SINTEF Health Research |
ClinicalTrials.gov Identifier: | NCT00447733 |
The purpose of this study is to determine whether integrated treatment is effective in the treatment of mental disorders and co-occurring substance use disorders.
Condition | Intervention | Phase |
---|---|---|
Anxiety Disorders Mood Disorders Substance Use Disorders |
Behavioral: Integrated mental health and substance misuse treatment |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Effects of Integrated Treatment to Persons With Mental Disorders and co-Occurring Substance Use Disorders |
Estimated Enrollment: | 150 |
Study Start Date: | April 2007 |
Estimated Study Completion Date: | December 2008 |
Patients with mental disorders and co-occuring substance use disorders are characterized by high suicide and treatment drop-out rates, and long-lasting interpersonal, work, school, health and legal problems. And because mental disorders and substance use disorders interact and co-exists, it may be important to provide treatment that integrates their substance misuse and mental health problems in a comprehensive way. The health services for patients with mental health and substance use disordes are usually provided by different services and health professionals that rarely cooperate or have qualifications on both kinds of disorders. The over-all aim of the study is to evaluate the effects of evidence-based integrated and comprehensive treatment of mental health problems and co-occurring substance use disorders. The effects of the treatment will be assesses on substance use,psychopathology, and quality of life.
Comparison: patients receiving treatment-as-usual or non-manualized treatment at general mental health outpatients clinics.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Rolf W. Grawe, Ph.D | 92221971 ext 47 | rolf.w.grawe@sintef.no |
Contact: Linda Wusthoff, cand.med. | 90569834 ext 47 | lindawusthoff@hotmail.com |
Norway | |
University of Oslo; Institute of Psychiatry | Recruiting |
Oslo, Norway, 0318 | |
Contact: Linda Wusthoff, cand.med. 90569834 ext 47 lindawusthoff@hotmail.com | |
Contact: Helge Waal 23368935 ext 47 helge.waal@uio.medisin.no | |
Principal Investigator: Linda Wusthoff, cand.med |
Principal Investigator: | Rolf W. Gråwe, Ph.D | SINTEF Health Research |
Study ID Numbers: | 78i068, NFR175394/V50 |
Study First Received: | March 14, 2007 |
Last Updated: | April 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00447733 History of Changes |
Health Authority: | Norway: Norwegian Social Science Data Services |
mental health substance use treatment |
Anxiety Disorders Mental Disorders Substance-Related Disorders Mood Disorders Disorders of Environmental Origin |
Pathologic Processes Disease Anxiety Disorders Mental Disorders |
Mood Disorders Substance-Related Disorders Disorders of Environmental Origin |